Q-omics provides the consensus-scored CSAG1 profile across patient tissues and cancer cell-line models. CSAG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CSAG1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CSAG1 RNA expression shows 6,614 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where CSAG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSAG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSAG1 survival associations across molecular data types. CSAG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSAG1 RNA expression–survival associations across cancer types. High CSAG1 expression shows unfavorable associations in KIRP, UVM, LIHC, ACC and UCEC, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CSAG1 RNA expression.
This table summarizes CSAG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSAG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSAG1 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LUAD, LUSC and LIHC. The HNSC box plot shows higher CSAG1 RNA expression in tumor versus normal tissue (log2 FC = +2.101, t-test p < 0.001).
This table shows molecular features associated with CSAG1 in patient tissues and cancer cell lines. In patient samples, CSAG1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CSAG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
